Zentalis Pharmaceuticals, Inc.
ZNTL
$2.76
$0.093.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 26.87M | 26.87M | 26.87M | 67.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 26.87M | 26.87M | 26.87M | 67.43M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 26.87M | 26.87M | 26.87M | 67.43M |
| SG&A Expenses | 32.43M | 68.67M | 72.49M | 81.96M | 87.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.92M | 179.45M | 197.14M | 227.39M | 254.88M |
| Operating Income | -140.92M | -152.58M | -170.28M | -200.52M | -187.46M |
| Income Before Tax | -136.62M | -149.52M | -163.02M | -224.15M | -165.69M |
| Income Tax Expenses | 442.00K | -205.00K | -232.00K | 34.00K | 177.00K |
| Earnings from Continuing Operations | -137.06 | -149.32 | -162.78 | -224.19 | -165.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | 0.00 | 0.00 | 28.00K |
| Net Income | -137.06M | -149.32M | -162.78M | -224.19M | -165.84M |
| EBIT | -140.92M | -152.58M | -170.28M | -200.52M | -187.46M |
| EBITDA | -140.19M | -151.68M | -169.22M | -199.29M | -186.17M |
| EPS Basic | -1.91 | -2.08 | -2.28 | -3.15 | -2.33 |
| Normalized Basic EPS | -1.08 | -1.22 | -1.34 | -1.69 | -1.27 |
| EPS Diluted | -1.91 | -2.08 | -2.28 | -3.15 | -2.33 |
| Normalized Diluted EPS | -1.08 | -1.22 | -1.34 | -1.69 | -1.27 |
| Average Basic Shares Outstanding | 287.47M | 287.08M | 286.05M | 285.10M | 284.32M |
| Average Diluted Shares Outstanding | 287.47M | 287.08M | 286.05M | 285.10M | 284.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |